Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Broad-spectrum COVID-19 vaccine (adenovirus vector)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal, Subcutaneous
01
Overview
This is a preclinical-stage broad-spectrum COVID-19 vaccine being developed by AIM Honesty (also known as AIM Bio). The vaccine utilizes an adenoviral vector platform to deliver SARS-CoV-2 antigens into host cells, which then express the antigens to trigger a robust and broad immune response. Unlike first-generation vaccines targeting a single strain, this candidate is specifically engineered to provide protection against multiple variants of the SARS-CoV-2 virus. According to company pipeline information, the vaccine is currently in the preclinical phase of development.
- Other names
- broad-spectrum COVID-19 vaccine (adenovirus vector)-AIM Honesty-SARS-CoV-2-viral vector vaccine (adenovirus)-COVID-19 (broad-spectrum/multiple variants)Adenovirus vector COVID-19 vaccineAIM Honesty broad-spectrum COVID-19 vaccine
Beyond the preview
Go deeper on Broad-spectrum COVID-19 vaccine (adenovirus vector).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Broad-spectrum COVID-19 vaccine (adenovirus vector).